Effects of a platelet activating factor antagonist on oedema formation following burns.
Deep dermal burns covering 30 per cent of the total body surface area were prepared by immersing the backs of rabbits in hot water at 80 degrees C for 20 s, to determine whether platelet activating factor (PAF) was involved in the onset of oedema following burns and to evaluate the effect of TCV-309, a potent PAF antagonist. The PAF antagonist, which was infused soon after the burn, blocked oedema formation in the wound and significantly (P < 0.001) inhibited PAF increase (P < 0.05) in the damaged tissue in a dose-dependent manner. This was confirmed by immunohistochemistry. In contrast, the superoxide dismutase content in the group treated with a high dose of TCV-309 was significantly (P < 0.01) higher than that of the control group. These findings suggest that administration of large doses of a PAF antagonist immediately after injury prevents oedema of burn wounds and the subsequent onset of burn shock by suppressing PAF and superoxide radical formation.
Ono
I
I
Department of Dermatology, Fukushima Medical College, Tokyo, Japan.
Gunji
H
H
Hasegawa
T
T
Harada
H
H
Kaneko
F
F
Matsuzaki
M
M
D000818:Animals; D001834:Body Water / Q000378:metabolism; D002056:Burns / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D004487:Edema / Q000150:complications / Q000378:metabolism / Q000473:pathology*; D007546:Isoquinolines / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011726:Pyridinium Compounds / Q000494:pharmacology*; D011817:Rabbits; D012867:Skin / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism; D044005:Tetrahydroisoquinolines
D007546:Isoquinolines; D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; D044005:Tetrahydroisoquinolines; D013482:Superoxide Dismutase; C067430:TCV 309